Alcon, a manufacturer eye care products, agreed to acquire EYSUVIS and INVELTYS from Kala Pharmaceuticals, a biopharmaceutical company, for $60m. “We will be pleased to add EYSUVIS to our growing pharmaceutical portfolio. EYSUVIS is a natural fit for our newly formed ophthalmic eye drop sales force in the United States. With our strong expertise in market access and commercial execution, we are well-positioned to build the market for acute dry eye treatment," Sergio Duplan, Alcon President, North America.